





# Antibody-Drug Conjugates from Discovery to Development:

Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical Design and Intellectual Property

Organizers: Mohan Srinivasan (Loxo/Lilly), Thomas Pillow (Genentech), Laurence Fayadat-Dilman (Merck)



San Francisco Bay Area: Crowne Plaza Foster City; available as webcast to other PBSS chapters



Mohan Srinivasan, PhD Associate VP, Biologics, Loxo/Lilly

**ADC Overview** 



Bernhard Geierstanger, PhD Co-Founder and CTO, Firefly Biologics

**Antibody Engineering for ADCs** 



**Travis Biechele, PhD**Senior Principal Scientist, **Merck** 

In-vitro and In-vivo Activity Considerations for ADCs



Hui Zhao, PhD
Senior Director of
Translational Biology,
Exelixis

**PK and Toxicology Study Designs** 



Maya Skubatch, JD
Partner at Wilson Sonsini
Goodrich & Rosati

**Intellectual Property of ADCs** 



Thomas Pillow, PhD
Distinguished Scientist,
Genentech

Chemistry of Linker Payload & Conjugation Techniques



Laurence Fayadat-Dilman, PhD Executive Director, Discovery Biologics, Merck

Analytical and Biophysical Characterization of ADCs



Judy Hsii, MS
Executive Director, Sutro
Biopharma

CMC Challenges and Opportunities in ADCs



Sara Glickstein Bar-Zeev, PhD Principal Clinical Scientist, Genentech

**Clinical Trial Design for ADCs** 

#### **Major Sponsors**











## Antibody-Drug Conjugates from **Discovery to Development:**

Chemistry, Engineering, Characterization, CMC, PK/Tox, **Clinical Design and Intellectual Property** 

Organizers: Mohan Srinivasan (Loxo/Lilly), Thomas Pillow (Genentech), Laurence Fayadat-Dilman (Merck)



San Francisco Bay Area: Crowne Plaza Foster City; available as webcast to other PBSS chapters

Time (PT)	Topic	Speaker
` ,	•	•
8:45 am - 8:55 am	PBSS Welcome Remarks	Shichang Miao, PhD, PBSS
8:55 am – 9:15 am	Workshop Overview and ADC overview (incl. target selection)	<b>Mohan Srinivasan</b> , PhD, Associate VP, Biologics, <b>Loxo/Lilly</b>
	, , , , , , , , , , , , , , , , , , , ,	
9:15 am - 10:00 am	Chemistry of Linker Payload & Conjugation Techniques	<b>Thomas Pillow</b> , PhD, Distinguished Scientist, <b>Genentech</b>
10:00 am - 10:45 am	Antibody Engineering for ADCs	<b>Bernhard Geierstanger</b> , PhD, Co-Founder and CTO, <b>Firefly Biologics</b>
10:45 am - 10:55 am	Major Sponsor Presentation	Resolian
10:55 am - 11:15 am	Break	-
11:15 am - 12:00 pm	Analytical and Biophysical Characterization of ADCs	Laurence Fayadat-Dilman, PhD, Executive Director, Discovery Biologics, Merck
12:00 pm - 12:50 pm	Lunch Break	Sponsor (Mycenax)
12:50 pm - 1:20 pm	In-vitro and In-vivo Activity Considerations for ADCs	Travis Biechele, PhD, Senior Principal Scientist, Merck
1:20 pm - 2:05 pm	CMC Challenges and Opportunities in ADCs	Judy Hsii, MS, Executive Director, Sutro Biopharma
2:05 pm - 2:50 pm	PK and Toxicology Study Designs	<b>Hui Zhao</b> , PhD, Senior Director of Translational Biology, <b>Exelixis</b>
2:50 pm - 3:00 pm	Major Sponsor Presentation	Alturas Analytics
3:00 pm - 3:20 pm	Break	-
3:20 pm - 4:05 pm	Clinical Trial Design for ADCs	Sara Glickstein Bar-Zeev, PhD, Principal Clinical Scientist, Genentech
4:05 pm - 4:50 pm	Intellectual Property of ADCs	Maya Skubatch, JD, Partner at Wilson Sonsini Goodrich & Rosati
4:50 pm - 5:30 pm	Panel Discussion & Closing Remarks	All Speakers
5:30 PM - 6:30 pm	Happy Hour	Sponsor (TBD)





### Antibody-Drug Conjugates from **Discovery to Development:**

Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical Design and Intellectual Property

Organizers: Mohan Srinivasan (Loxo Oncology at Lilly), Thomas Pillow (Genentech), Laurence Fayadat-Dilman (Merck)

San Francisco Bay Area: Crowne Plaza Foster City, available as webcast to other PBSS chapters

#### **Sponsors**























